Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles

Acta Biomaterialia

Volumn 14, Issue , 2015, Pages 115-124

  Yu, Pengcheng ^a,b   Yu, Haijun ^b   Guo, Chengyue ^b   Cui, Zhirui ^b   Chen, Xianzhi ^b   Yin, Qi ^b   Zhang, Pengcheng ^b,c   Yang, Xiangliang ^a   Cui, Honggang ^c   Li, Yaping ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c Johns Hopkins University   (United States)

Author keywords

Breast cancer; Doxorubicin; Mitochondria; Multidrug resistance; PH responsive

Indexed keywords

BIOELECTRIC POTENTIALS; CELL CULTURE; CELL DEATH; CHEMOTHERAPY; DISEASES; MICELLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS;

BREAST CANCER; CANCER CELLS; DIBLOCK-COPOLYMER; DOXORUBICIN; EFFECTIVE APPROACHES; MITOCHONDRIAS; MULTIDRUG RESISTANCE; PH-RESPONSIVE; PH-RESPONSIVE MICELLES; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATES;

MITOCHONDRIA;

DOXORUBICIN; MACROGOL; TOCOFERSOLAN; ALPHA TOCOPHEROL; MICELLE; POLY(2-(DIISOPROPYLAMINO)ETHYL METHACRYLATE); POLYMETHACRYLIC ACID DERIVATIVE;

ACIDITY; ALKALINITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DISSOCIATION; DNA DAMAGE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENTIATION; DRUG RELEASE; DRUG SENSITIVITY; DRUG UPTAKE; ENDOCYTOSIS; EX VIVO STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MICROENVIRONMENT; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULAR WEIGHT; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TUMOR VOLUME; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL CYCLE; CELL DEATH; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MICELLE; NUDE MOUSE; PATHOLOGY; PH; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALIA; MUS MUSCULUS;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MCF-7 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED BALB C; MICE, NUDE; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; POLYMETHACRYLIC ACIDS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; VITAMIN E;

EID: 84921873286     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.12.001     Document Type: Article

References (38)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001;344:783-92.
2. Smith IC, Heys SD, Hutckeon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
3. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein-synthesis in cell-free systems and intact-cells. Cancer Res 1976;36:2891-5.
4. Pang BX, Qiao XH, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Druginduced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013:4. http://dx.doi.org/10.1038/ ncomms2921.
5. Sun TM, Wang YC, Wang F, Du JZ, Mao CQ, Sun CY, et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014;35:836-45.
6. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
7. Chatterjee K, Zhang JQ, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010;115:155-62.
8. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
9. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009;26:1816-31.
10. Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 2002;3:1652-9.
11. Porteous CM, Menon DK, Aigbirhio FI, Smith RA, Murphy MP. P-glycoprotein (MDR1a/1b) and breast cancer resistance protein (BCRP) decrease the uptake of hydrophobic alkyl triphenylphosphonium cations by the brain. Biochim Biophys Acta 2013;1830:3458-65.
12. Saneja A, Khare V, Alam N, Dubey RD, Gupta PN. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Exp Opin Drug Delivery 2014;11:121-38.
13. Mao G, Kraus GA, Kim I, Spurlock ME, Bailey TB, Beitz DC. Effect of a mitochondria-targeted vitamin E derivative on mitochondrial alteration and systemic oxidative stress in mice. Br J Nutr 2011;106:87-95.
14. Wang XX, Li YB, Yao HJ, Ju RJ, Zhang Y, Li RJ, et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011;32:5673-87.
15. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010;9:447-64.
16. Dong LF, Jameson VJA, Tilly D, Cerny J, Mahdavian E, Marin-Hernandez A, et al. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Chem 2010;286:3717-28.
17. Cheng G, Zielonka J, McAllister DM, Mackinnon Jr AC, Joseph J, Dwinell MB, et al. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer 2013;13:285.
18. Zhang Z, Liu Z, Ma L, Jiang S, Wang Y, Yu H, et al. Reversal of multidrug resistance by mitochondrial targeted self-assembled nanocarrier based on stearylamine. Mol Pharm 2013;10:2426-34.
19. Cheng G, Zielonka J, Dranka BP, McAllister D, Mackinnon Jr AC, Joseph J, et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res 2012;72:2634-44.
20. Fan Z, Wu J, Fang X, Sha X. A new function of Vitamin E-TPGS in the intestinal lymphatic transport of lipophilic drugs: enhancing the secretion of chylomicrons. Int J Pharm 2013;445:141-7.
21. Rodríguez-Enríquez S, Hernández-Esquivel L, Marín-Hernández A, Dong L-F, Akporiaye ET, Neuzil J, et al. Molecular mechanism for the selective impairment of cancer mitochondrial function by a mitochondrially targeted vitamin E analogue. Biochim Biophys Acta 2012;1817:1597-607.
22. Prochazka L, Dong L-F, Valis K, Freeman R, Ralph S, Turanek J, et al. a- Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis 2010;15:782-94.
23. Mi Y, Liu Y, Feng SS. Formulation of Docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 2011;32:4058-66.
24. Guo YY, Chu M, Tan SW, Zhao S, Liu HX, Otieno BO, et al. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance. Mol Pharm 2014;11:59-70.
25. Shen JA, Sun HP, Xu PF, Yin Q, Zhang ZW, Wang SL, et al. Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials 2013;34:1581-90.
26. Yu HJ, Xu ZA, Wang DG, Chen XZ, Zhang ZW, Yin Q, et al. Intracellular pHactivated PEG-b-PDPA wormlike micelles for hydrophobic drug delivery. Polym Chem 2013;4:5052-5.
27. Yu HJ, Zou YL, Jiang L, Yin Q, He XY, Chen LL, et al. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials 2013;34:2738-47.
28. Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol 2010;11:50-61.
29. Du JZ, Armes SP. PH-responsive vesicles based on a hydrolytically self-crosslinkable copolymer. J Am Chem Soc 2005;127:12800-1.
30. Yu H, Xu Z, Chen X, Xu L, Yin Q, Zhang Z, et al. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel. Macromol Biosci 2014;14:100-9.
31. Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013;7:5858-69.
32. Shen JA, Yin Q, Chen LL, Zhang ZW, Li YP. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012;33:8613-24.
33. Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol 2010;11:50-61.
34. Zhang ZW, Liu ZY, Ma L, Jiang SJ, Wang YX, Yu HJ, et al. Reversal of multidrug resistance by mitochondrial targeted self-assembled nanocarrier based on stearylamine. Mol Pharm 2013;10:2426-34.
35. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
36. Carlson AL, Fujisaki J, Wu J, Runnels JM, Turcotte R, Spencer JA, et al. Tracking single cells in live animals using a photoconvertible near-infrared cell membrane label. PLoS ONE 2013;8:e69257.
37. Moghimi SM, Hunter AC, Murray JC. Longcirculating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
38. Hayward R, Hydock DS. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci: JAALAS 2007;46:20-32.